Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter

Journal of Controlled Release

Volumn 117, Issue 1, 2007, Pages 1-10

  Gommans, W M ^a   McLaughlin, P M J ^b   Schalk, J A C ^c   Groothuis, G M M ^a   Haisma, H J ^a   Rots, M G ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Laboratory Medicine   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

CRAd; EpCAM; GA733 2; Human liver slices; Tumor specific promoter; Virotherapy

Indexed keywords

CRAD; EPCAM; GA733-2; HUMAN LIVER SLICES; TUMOR SPECIFIC PROMOTERS; VIROTHERAPY;

DRUG THERAPY; GENES; ONCOLOGY; TISSUE; TUMORS;

VIRUSES;

ADENOVIRUS VECTOR; EPITHELIAL GLYCOPROTEIN 2; GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CARCINOMA; CELL KILLING; CELL LINE; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO CULTURE; LIVER SLICE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, SURFACE; CARCINOMA; CELL LINE, TUMOR; DISEASE VECTORS; ESCHERICHIA COLI; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 33846474902     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.10.006     Document Type: Article

References (53)

1. Immonen A., Vapalahti M., Tyynela K., Hurskainen H., Sandmair A., Vanninen R., Langford G., Murray N., and Yla-Herttuala S. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Molec. Ther. 10 5 (2004) 967-972
2. Sandmair A.M., Loimas S., Puranen P., Immonen A., Kossila M., Puranen M., Hurskainen H., Tyynela K., Turunen M., Vanninen R., Lehtolainen P., Paljarvi L., Johansson R., Vapalahti M., and Yla-Herttuala S. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11 16 (2000) 2197-2205
3. Wood M., Perrotte P., Onishi E., Harper M.E., Dinney C., Pagliaro L., and Wilson D.R. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther. 6 4 (1999) 367-372
4. van der Eb M.M., Cramer S.J., Vergouwe Y., Schagen F.H., van Krieken J.H., van der Eb A.J., Rinkes I.H., van de Velde C.J., and Hoeben R.C. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther. 5 4 (1998) 451-458
5. Yamamoto M., Alemany R., Adachi Y., Grizzle W.E., and Curiel D.T. Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Molec. Ther. 3 3 (2001) 385-394
6. Haviv Y.S., and Curiel D.T. Conditional gene targeting for cancer gene therapy. Adv. Drug Deliv. Rev. 53 2 (2001) 135-154
7. Enger P.O., Thorsen F., Lonning P.E., Bjerkvig R., and Hoover F. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Hum. Gene Ther. 13 9 (2002) 1115-1125
8. Huebner R.J., Rowe W.P., Schatten W.E., Smith R.R., and Thomas L.B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9 6 (1956) 1211-1218
9. Kirn D., Martuza R.L., and Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7 7 (2001) 781-787
10. Haviv Y.S., and Curiel D.T. Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr. Gene Ther. 3 4 (2003) 357-385
11. Rots M.G., Curiel D.T., Gerritsen W.R., and Haisma H.J. Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J. Control. Release 87 1-3 (2003) 159-165
12. Hallenbeck P.L., Chang Y.N., Hay C., Golightly D., Stewart D., Lin J., Phipps S., and Chiang Y.L. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10 10 (1999) 1721-1733
13. Matsubara S., Wada Y., Gardner T.A., Egawa M., Park M.S., Hsieh C.L., Zhau H.E., Kao C., Kamidono S., Gillenwater J.Y., and Chung L.W. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 61 16 (2001) 6012-6019
14. Zhang J., Ramesh N., Chen Y., Li Y., Dilley J., Working P., and Yu D.C. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res. 62 13 (2002) 3743-3750
15. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., and Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57 13 (1997) 2559-2563
16. Gommans W.M., van Eert S.J., McLaughlin P.M., Harmsen M.C., Yamamoto M., Curiel D.T., Haisma H.J., and Rots M.G. The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. Cancer Gene Ther. 13 2 (2006) 150-158
17. McLaughlin P.M., Trzpis M., Kroesen B.J., Helfrich W., Terpstra P., Dokter W.H., Ruiters M.H., de Leij L.F., and Harmsen M.C. Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines. Cancer Gene Ther. 11 9 (2004) 603-612
18. Balzar M., Winter M.J., de Boer C.J., and Litvinov S.V. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. 77 10 (1999) 699-712
19. Winter M.J., Nagtegaal I.D., van Krieken J.H., and Litvinov S.V. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am. J. Pathol. 163 6 (2003) 2139-2148
20. de Boer C.J., van Krieken J.H., Janssen-van Rhijn C.M., and Litvinov S.V. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J. Pathol. 188 2 (1999) 201-206
21. Rots M.G., Elferink M.G., Gommans W.M., Oosterhuis D., Schalk J.A., Curiel D.T., Olinga P., Haisma H.J., and Groothuis G.M. An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents. J. Gene Med. 8 1 (2006) 35-41
22. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95 5 (1998) 2509-2514
23. Yamamoto M., Davydova J., Takayama K., Alemany R., and Curiel D.T. Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with e1 deleted. J. Virol. 77 2 (2003) 1633-1637
24. Alemany R., and Curiel D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8 17 (2001) 1347-1353
25. Ranheim T.S., Shisler J., Horton T.M., Wold L.J., Gooding L.R., and Wold W.S. Characterization of mutants within the gene for the adenovirus E3 14.7-kilodalton protein which prevents cytolysis by tumor necrosis factor. J. Virol. 67 4 (1993) 2159-2167
26. Smith T., Idamakanti N., Kylefjord H., Rollence M., King L., Kaloss M., Kaleko M., and Stevenson S.C. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Molec. Ther. 5 6 (2002) 770-779
27. Haisma H.J., Pinedo H.M., Rijswijk A., der Meulen-Muileman I., Sosnowski B.A., Ying W., Beusechem V.W., Tillman B.W., Gerritsen W.R., and Curiel D.T. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther. 6 8 (1999) 1469-1474
28. Heideman D.A., Snijders P.J., Craanen M.E., Bloemena E., Meijer C.J., Meuwissen S.G., van V. B., Pinedo H.M., Curiel D.T., Haisma H.J., and Gerritsen W.R. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther. 8 5 (2001) 342-351
29. Kraaij R., van Rijswijk A.L., Oomen M.H., Haisma H.J., and Bangma C.H. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate 62 3 (2005) 253-259
30. DeWeese T.L., van der P.H., Li S., Mikhak B., Drew R., Goemann M., Hamper U., DeJong R., Detorie N., Rodriguez R., Haulk T., DeMarzo A.M., Piantadosi S., Yu D.C., Chen Y., Henderson D.R., Carducci M.A., Nelson W.G., and Simons J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61 20 (2001) 7464-7472
31. Makower D., Rozenblit A., Kaufman H., Edelman M., Lane M.E., Zwiebel J., Haynes H., and Wadler S. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. 9 2 (2003) 693-702
32. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., Randlev B., Heise C., Uprichard M., Hatfield M., Rome L., Rubin J., and Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 62 21 (2002) 6070-6079
33. Heise C.C., Williams A.M., Xue S., Propst M., and Kirn D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59 11 (1999) 2623-2628
34. Huang T.G., Savontaus M.J., Shinozaki K., Sauter B.V., and Woo S.L. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther. 10 15 (2003) 1241-1247
35. Jakubczak J.L., Ryan P., Gorziglia M., Clarke L., Hawkins L.K., Hay C., Huang Y., Kaloss M., Marinov A., Phipps S., Pinkstaff A., Shirley P., Skripchenko Y., Stewart D., Forry-Schaudies S., and Hallenbeck P.L. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res. 63 7 (2003) 1490-1499
36. Li Y., Yu D.C., Chen Y., Amin P., Zhang H., Nguyen N., and Henderson D.R. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 61 17 (2001) 6428-6436
37. McCart J.A., Wang Z.H., Xu H., Hu Y., Park B., Alexander H.R., and Bartlett D.L. Development of a melanoma-specific adenovirus. Molec. Ther. 6 4 (2002) 471-480
38. Nettelbeck D.M., Rivera A.A., Balague C., Alemany R., and Curiel D.T. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 62 16 (2002) 4663-4670
39. Yu D.C., Chen Y., Dilley J., Li Y., Embry M., Zhang H., Nguyen N., Amin P., Oh J., and Henderson D.R. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 61 2 (2001) 517-525
40. Stoff-Khalili M.A., Stoff A., Rivera A.A., Banerjee N.S., Everts M., Young S., Siegal G.P., Richter D.F., Wang M., Dall P., Mathis J.M., Zhu Z.B., and Curiel D.T. Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system. Breast Cancer Res. 7 6 (2005) R1141-R1152
41. Momburg F., Moldenhauer G., Hammerling G.J., and Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 47 11 (1987) 2883-2891
42. Suzuki K., Alemany R., Yamamoto M., and Curiel D.T. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res. 8 11 (2002) 3348-3359
43. Tollefson A.E., Scaria A., Hermiston T.W., Ryerse J.S., Wold L.J., and Wold W.S. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70 4 (1996) 2296-2306
44. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., Hawkins L., and Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6 10 (2000) 1134-1139
45. Alemany R., Suzuki K., and Curiel D.T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81 Pt 11 (2000) 2605-2609
46. Hitt M.M., and Graham F.L. Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 179 2 (1990) 667-678
47. Steinwaerder D.S., and Lieber A. Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther. 7 7 (2000) 556-567
48. Vassaux G., Hurst H.C., and Lemoine N.R. Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. 6 6 (1999) 1192-1197
49. Yamamoto M., Davydova J., Wang M., Siegal G.P., Krasnykh V., Vickers S.M., and Curiel D.T. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125 4 (2003) 1203-1218
50. Glasgow J.N., Bauerschmitz G.J., Curiel D.T., and Hemminki A. Transductional and transcriptional targeting of adenovirus for clinical applications. Curr. Gene Ther. 4 1 (2004) 1-14
51. Kanerva A., Wang M., Bauerschmitz G.J., Lam J.T., Desmond R.A., Bhoola S.M., Barnes M.N., Alvarez R.D., Siegal G.P., Curiel D.T., and Hemminki A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Molec. Ther. 5 6 (2002) 695-704
52. Rots M.G., Gommans W.M., Dmitriev I., Oosterhuis D., Seki T., Curiel D.T., and Haisma H.J. A platform for constructing infectivity-enhanced fiber-mosaic adenoviruses genetically modified to express two fiber types. Gene Ther. Mol. Biol. 8 (2004) 423-430
53. Taki M., Kagawa S., Nishizaki M., Mizuguchi H., Hayakawa T., Kyo S., Nagai K., Urata Y., Tanaka N., and Fujiwara T. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 24 19 (2005) 3130-3140